Driehaus Capital Management LLC Has $3.53 Million Stake in Design Therapeutics, Inc. $DSGN

Key Points

• Driehaus Capital Management LLC increased its position in Design Therapeutics, Inc. by 17.7%, acquiring an additional 137,317 shares during the first quarter.
• Design Therapeutics reported a loss of ($0.34) earnings per share, missing the consensus estimate by ($0.02) for the most recent quarter.
• The stock price of Design Therapeutics has experienced a decline of 2.0%, with current trading at $5.53 per share.

Driehaus Capital Management LLC grew its position in shares of Design Therapeutics, Inc. (NASDAQ:DSGN - Free Report) by 17.7% during the 1st quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 913,399 shares of the company's stock after buying an additional 137,317 shares during the period. Driehaus Capital Management LLC owned approximately 1.61% of Design Therapeutics worth $3,526,000 at the end of the most recent quarter.

Other institutional investors also recently modified their holdings of the company. Frazier Life Sciences Management L.P. grew its stake in shares of Design Therapeutics by 3.2% in the fourth quarter. Frazier Life Sciences Management L.P. now owns 1,953,547 shares of the company's stock valued at $12,053,000 after acquiring an additional 61,000 shares in the last quarter. Point72 Asset Management L.P. raised its holdings in shares of Design Therapeutics by 16.0% during the 4th quarter. Point72 Asset Management L.P. now owns 1,856,750 shares of the company's stock worth $11,456,000 after buying an additional 256,010 shares in the last quarter. MPM Bioimpact LLC bought a new stake in shares of Design Therapeutics during the 4th quarter worth $3,452,000. Northern Trust Corp boosted its stake in Design Therapeutics by 15.2% in the fourth quarter. Northern Trust Corp now owns 388,125 shares of the company's stock valued at $2,395,000 after buying an additional 51,351 shares in the last quarter. Finally, Dimensional Fund Advisors LP grew its position in Design Therapeutics by 60.2% in the fourth quarter. Dimensional Fund Advisors LP now owns 215,265 shares of the company's stock valued at $1,328,000 after acquiring an additional 80,905 shares during the last quarter. Institutional investors own 56.64% of the company's stock.

Design Therapeutics Trading Up 1.9%

NASDAQ DSGN traded up $0.12 during trading on Thursday, hitting $6.08. 71,476 shares of the company's stock were exchanged, compared to its average volume of 135,730. The company has a market cap of $345.97 million, a PE ratio of -5.42 and a beta of 1.61. Design Therapeutics, Inc. has a fifty-two week low of $2.60 and a fifty-two week high of $7.77. The stock's 50 day moving average price is $4.43 and its two-hundred day moving average price is $4.17.

Design Therapeutics (NASDAQ:DSGN - Get Free Report) last announced its quarterly earnings results on Thursday, August 7th. The company reported ($0.34) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.32) by ($0.02). Analysts forecast that Design Therapeutics, Inc. will post -0.91 earnings per share for the current fiscal year.

About Design Therapeutics

Design Therapeutics, Inc a biopharmaceutical company, researches, designs, develops, and commercializes small molecule therapeutic drugs for the treatment of genetic diseases in the United States. The company utilizes its GeneTAC platform to design and develop therapeutic candidates for inherited diseases caused by nucleotide repeat expansion.